Skip to main content
Clinical Trials/NCT03397030
NCT03397030
Completed
N/A

Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer

The University of Texas Health Science Center at San Antonio2 sites in 1 country27 target enrollmentJanuary 5, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostatic Neoplasm
Sponsor
The University of Texas Health Science Center at San Antonio
Enrollment
27
Locations
2
Primary Endpoint
Change in concentration of circulating Prognostic Biomarkers
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The goal of this study is to demonstrate the impact of a home based exercise program versus wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer under active surveillance.

Detailed Description

Prostate cancer (PCa) is the most common non-skin cancer effecting American males. Several reports suggest that physical activity after cancer diagnosis is associated with better cancer- specific and overall survival in individuals diagnosed with PCa. There is a growing body of evidence for lifestyle interventions that aim to promote physical activity as having the potential to counter some of the adverse effects of cancer treatments, disease progression and other health outcomes. Exercise performed 2-3 times a week has been shown to improve physical fitness, functional performance, and quality of life in men with PCa; however, few men with PCa exercise regularly and do not meet national physical activity guidelines. A potential explanation on the lack of exercise in men with PCa is the absence of a structured, home-based, exercise program. While studies have shown positive effects of exercise in men with PCa, little is known about how physical activity effects tumor physiology in men with PCa. The primary objective of this pilot study is to gather preliminary data regarding the impact of a novel, home-based exercise program on PCa biomarkers associated with recurrence and metastasis of PCa in men under active surveillance.

Registry
clinicaltrials.gov
Start Date
January 5, 2017
End Date
November 19, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Men aged 40 or older
  • Ambulating male
  • Diagnosed with low grade prostate cancer
  • Subjects willing and able to provide consent to participating in the study Exclusion Criteria
  • prostatectomy
  • severe cardiac disease (New York Heart Association class III or greater)
  • severe osteoporosis
  • uncontrolled hypertension (blood pressure \> 160/95mm Hg)
  • uncontrolled sinus tachycardia (\> 120 beats per minute)
  • uncontrolled congestive heart failure third-degree atrio-ventricular heart block, active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein thrombosis, resting ST displacement (\> 3mm), uncontrolled diabetes, uncontrolled pain, cognitive impairment, history of falls due to balance impairment or lost of consciousness,

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in concentration of circulating Prognostic Biomarkers

Time Frame: Baseline Visit, Week 12 visit, Week 18 visit and Week 24 visit.

Analyze concentrations of Prostate-specific antigen (PSA), Prostate-specific membrane antigen (PSMA), Early prostate cancer antigen (EPCA), Urokinase plasminogen activator (uPA), and Urokinase plasminogen activator receptor (uPAR) in serum collected at each visit with research staff.

Secondary Outcomes

  • Fatigue Biomarker Index(Baseline Visit, Week 12 visit, Week 18 visit and Week 24 visit.)

Study Sites (2)

Loading locations...

Similar Trials